Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Puretech Health plc (PRTC) Ordinary 1p

Sell:239.00p Buy:242.00p 0 Change: No change
FTSE 250:0.04%
Market closed Prices as at close on 18 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:239.00p
Buy:242.00p
Change: No change
Market closed Prices as at close on 18 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:239.00p
Buy:242.00p
Change: No change
Market closed Prices as at close on 18 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.

Contact details

Address:
501 Boylston St Ste 6102
BOSTON
02116-3769
United States
Telephone:
+1 (0617) 4822333
Website:
puretechhealth.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 27 August 2019 27/08/19
AGM 29 May 2019 29/05/19
Final results 24 April 2019 24/04/19

General stock information

EPIC:
PRTC
ISIN:
GB00BY2Z0H74
Market cap:
£718.86 million
Shares in issue:
285.26 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE 250,FTSE 350,FTSE All Share

Key personnel

  • Daphne Zohar
    Chief Executive Officer, Co-Founder, Director
  • Robert Langer
    Co-Founder, Non-Executive Director
  • Bennett Shapiro
    Co-Founder, Non-Executive Director
  • Bernat Olle
    Venture Partner
  • Joep Muijrers
    Chief Financial Officer
  • Stephen Muniz
    Executive Vice President - Legal, Finance and Operations
  • Eric Elenko
    Executive Vice President - Science & Technology
  • David Steinberg
    Executive Vice President - Company Creation
  • Joseph Bolen
    Chief Scientific Officer
  • Spencer Ball
    Vice President - Talent Acquisition

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.